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1. Introduction
Since the emergence of the acquired immune deficiency syndrome (AIDS), there has been a
great deal of interest in identifying cofactors that accelerate progression of the disease elicit‐
ed by human immunodeficiency virus types 1 or 2 (HIV-1, HIV-2). Beside inherent factors
and environmental agents, speculations led to the conclusion that infectious diseases fre‐
quently occur in HIV infected persons, might augment HIV replication, and consequently
facilitate AIDS progression. HIV infection is followed by a long disease-free period, during
which a low number of CD4+ immune cells contains transcriptionally silent provirus. Acti‐
vation of CD4+ cells by external factors, including heterologous viruses, terminates latency
forcing towards a productive HIV infection. Transactivation of the HIV long terminal repeat
(LTR) by cellular, nuclear transcriptional factors (e.g. NF-κB, Sp1) induced by mitogens, cy‐
tokines, chemokines, simultaneous virus infections is followed by gene expression including
the synthesis of the HIV transactivator protein (TAT), which binds to the transactivating re‐
sponse (TAR) element of the genome, ultimately leading to large scale production of HIV
and death of infected cells through apoptosis [1,2]. In vitro studies showed that products of
immediate early (IE) or early (E) genes of several DNA viruses such as human herpesviruses
(HHV) -1, 2, 3, 4, 5, 6A, 8, adenoviruses, as well as hepatitis B virus (HBV) X gene, human T
lymphotropic virus type I (HTLV-I) tax gene upregulated production of these transcriptional
factors and activate HIV-1 or HIV-2 in the same cells. Simultaneous infection in a single cell
is relatively rare event in vivo; therefore such type of biological effects in nature could be
minimal. On the contrary, cross-talk between immune cells carrying different viruses via cy‐
tokines, chemokines is more common. Heterologous viruses infect many types of cells,
which are not targets of HIV, but release several immunomodulatory mediators, usually in
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an abnormal pattern. High level of tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-10,
and low level of IL-2, IL-12 were frequently observed in the blood of AIDS patients, only to
mention the most important ones. Abundant pro-inflammatory cytokines bind to HIV carri‐
er cells and through consequently activated secondary messenger systems activate the same
transcriptional factors for HIV activation. This category of interaction has a more significant
impact on HIV infection. This phenomenon called as transcellular transactivation can last
lifetime, its intensity may vary depending on the host, the other transiently or chronically
coinfecting microbes, etc. [3]. These external confounding factors act in a pleiotropic man‐
ner, which is impossible to study in vitro. Animal studies are ideal to establish their role in
AIDS progression [4].
2. The feline AIDS model
Feline AIDS (FAIDS) induced by feline immunodeficiency virus (FIV) is the only natural
small animal model of human AIDS [4,5-8 ]. FIV shares many genetic, structural and biologi‐
cal characteristics with HIV. FIV also shows tropism for CD4+ immune cells, but its receptor
is the CD134 molecule with the CXCR4 coreceptor. FIV LTR accommodates multiple en‐
hancer or promoter protein-binding sites (e.g. NF-κB, AP-1). Although FIV lacks TAT and
the TAR element, its Orf-2 (also designated as Orf-A) acts as a transactivator gene to some
degree and is necessary for productive FIV replication [7,9]. The similarities in the clinical
course of infection between HIV and FIV are striking [6,8,10]. Male gender and adult age are
known risk factors for both HIV and FIV transmission [6,7,11,12]. Domestic cats infected
with FIV develop progressive immune dysfunction characterised by depletion of CD4+ T
cells, wasting, cachexia, gingivostomatitis, neuropathological disorders, opportunistic infec‐
tions, unusual malignancies such as B cell lymphomas, fibrosarcomas [13]. CD4+CD25+hi‐
FoxP3+ immunosuppressive regulatory T (Treg) cells have been implicated as a possible
cause of immune dysfunction during FIV and HIV-1 infection, as they are capable of modu‐
lating virus-specific and inflammatory immune responses. Influence of Treg cell suppres‐
sion during FIV and HIV pathogenesis is most prominent after Treg cells are activated in the
environment of established FIV infection [10]. It is important to remember that increased ac‐
tivity of Treg cells promotes immunosenescence in the normal elderly, and AIDS is regarded
as an extremely rapid ageing process [14]. Disease progression occurs over a similar time
scale to HIV-1 infection in humans [6]. FIV is distributed worldwide; it has several subtypes
similarly to HIV [12,15]. Species-specific strains of FIV circulate in many members of Felidae
family, including endangered big cats in which also induce AIDS-like illnesses [6,12]. Some
opportunistic infections in cats also occur worldwide such as feline leukaemia virus (FeLV),
feline herpesvirus type 1 (FHV-1), Toxoplasma gondii (TG), feline coronavirus (FCoV), Barto‐
nella henselae (BH), canine distemper virus (CDV), fungal pathogens or mycoplasmas. Their
incidence depends on geographical regions, cat subpopulations (pet, indoor, stray, feral,
free-roaming, etc.), gender and age [11,12,16-28]. Incidence of other opportunistic microbes
depends on endemic geographical areas and local vectors (e.g. haemoplasma or Leishmania
species, different helminths) [16,18,29-33]. Some of these microbes establish coinfection in a
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particular felid species that carries a specific strain of FIV. Typical examples have been re‐
ported recently. A highly virulent FeLV outbreak in FIVPco infected free ranging Florida pu‐
mas (Puma concolor coryi) threatened this endangered species [12]. In another outbreak in the
Serengeti, FIVPle B infected lions (Panthera leo) were twice as likely to survive CDV infection
compared to lions infected with FIVPle A or FIVPle C [34]. These cases clearly demonstrate
that specificities of both microbes might express increased risk for severe synergistic patho‐
genicity. Recent surveys on coinfections mentioned above were carried out for descriptive
epidemiological purposes. In the majority of studies, occurrence of heterologous microbes
were judged as opportunistic infections, but some of the investigators have come to the con‐
clusion that FIV and heterologous microbes might mutually aggravate immunosuppression
at the level of the organism [12,17]. Both FIV and FeLV independently might predispose ani‐
mals for toxoplasma infection [21]. In spite of similar clinical manifestations by FIV or FeLV,
they might specifically predispose the host for different heterologous microbial pathogens:
FIV predisposes to Leishmania [12,16], mycoplasma [25,27,33,35], fungal [26], FCoV [12] in‐
fections, while FeLVsensitises the organism to BH infection [36]. Others found that the rate
of toxoplasma [16,30,32] or FCV [24] infections occur independently of FIV status. These re‐
sult, even some of them are contradictory, clearly show that each retrovirus must have its
specific way to interact with other microbes at molecular or immunological level. It is con‐
ceivable that HIV and human microbes have similar ways for interactions. Both direct trans‐
activation of FIV in the simultaneously infected cells (Figure 1) or cross-talk between cells
infected by FIV, and other cells infected by heterologous microbes (Figure 2) can take place
in the body of cats.
Figure 1. Scheme of intracellular virus transactivation
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Figure 2. Scheme of transcellular transactivation
Comparison of human clinical observations on opportunistic infections in HIV infected pa‐
tients and in vitro transactivation studies unambiguously demonstrate that several viruses
can cause both opportunistic infection and transactivate HIV. The domestic cat is afflicted
with multiple microbes that also induce human diseases (e.g. TG, Leishmania, fungi, myco‐
bacteria). Furthermore, domestic cats harbour several feline virus species that are homolo‐
gous to human viruses: FIV, FeLV, FHV, FCV, FCoV, as well as feline sarcoma virus, feline
parvovirus, feline morbillivirus [12]. These feline microbe species provide a panoply of in‐
fectious disease models for many devastating human diseases including for studies on the
possible interaction between retroviruses and heterologous microbes among natural condi‐
tions of FAIDS at molecular, immunological, cellular level in any organ or the whole body of
infected cats by any available methodology.
3. Simultaneous infections: Both opportunists and transactivators
3.1. Feline herpesvirus
Simultaneous infection by retroviruses and heterogenous microbes and their association
with a variety of diseases have come into focus recently. The very sensitive methods to de‐
tect nucleic acids of microbes have promoted our understanding that microbial interaction
may result in the synergistic induction of more severe disease course. Retroviruses and her‐
pesviruses might be associated with a variety of diseases in animals. Coinfection of chickens
with Marek’s disease virus (Gammaherpesvirinae) and retrovirus (avian leukosis virus) in‐
crease the incidence of retrovirus associated tumours [37]. As several species of human her‐
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pesviruses have been implicated as cofactors for AIDS progression, possible interaction of
feline herpesvirus 1 (FHV-1, subfamily Betaherpesvirinae, a homologue of human cytomega‐
lovirus /CMV/), with FIV has been studied in vivo and in vitro. FHV-1 might spread in some
captive felids with higher frequency than in their free-ranging counterparts demonstrating
the importance of human intervention in natural epidemiology [11,29,38]. Single or simulta‐
neous infection by FHV-1 and TG or BH have been implicated as causative agents of feline
uveitis [20]. It is of note, that FHV-1 homologue human CMV induces very severe retinitis in
HIV infected humans [12], and human CMV was found one of the clinically most frequent
and strongest transactivator of HIV. On the contrary to human experience with HSV-1 and
adenoviruses [39], FHV-1 could not be implicated in the multifactorial aetiology of gingivitis
[24]. FHV-1 also infects T lymphocytes. FHV-1 is a significant pathogen limited to the family
Felidae, causing an upper respiratory disease in cats. Interaction of acute FHV-1 infection in
chronically, experimentally FIV infected specific pathogen-free (SPF) animals results in sev‐
eral immunological abnormalities. FIV infected cats produce less FHV-1 neutralising IgM
antibodies during the first 3 weeks of infection than non-FIV infected animals, whereas the
IgG antibody response remains unaffected. The ongoing IgG antibody response to FIV is not
affected by FHV-1 infection. Lymphocyte blastogenic response to concanavalin A (Con-A) is
depressed in FIV-infected and non-infected cats, but response to pokeweed mitogen (PWM)
takes longer to return to normal in FIV infected animals. Lymphocytes from FIV infected
cats have a greater and more sustained proliferative response to FHV-1 antigen than non-
infected cats [40]. Cats with pre-existing FIV infection have more severe signs of disease af‐
ter exposure to FHV-1 or TG, than FIV-free counterparts. Primary immune responses to all
heterologous pathogens are delayed or diminished in FIV infected compared with non-FIV-
infected animals. Repeated infections have no significant effect on the level of FIV-specific
antibodies or on the production of peripheral blood mononuclear cells (PBMC) containing
FIV proviral DNA. FIV infected cats exposed to cofactors have normal levels of IL-2R and
major histocompatibility complex (MHC)-II antigen expression on PBMCs, while only-FIV-
infected animals have upregulated IL-2R and down-regulated MHC-II expression [41]. By
transfection of a recombinant plasmid containing the FIV LTR linked to the chloramphenicol
acetyltransferase (CAT) gene, followed by infection of FHV-1 into Crandell feline kidney
(CrFK) or Felis catus whole fetus 4 (fcwf-4) cells enhancement of CAT activity was demon‐
strated. Both immunofluorescence and electron microscopy showed productive coinfection
of individual T lymphocytes [42]. A series of FIV LTR deletion mutants were constructed
and cotransfected with FHV-1 to identify the regions that are responsible for transactivation.
It was demonstrated that sequences between -124 and -79, and between -21 and -32 (relative
to the cap site) are essential of FIV replication in fcwf-4 cells and that the sequence between
-63 and -23 responds to transactivation of FIV LTR by FHV-1 [43]. FHV-1 infected-cell-pro‐
tein 4 (ICP4) was found to down-regulate FIV LTR directed gene expression via the C/EBP
site in the LTR, but after introduction of a site-specific mutation of this site, ICP4 significant‐
ly stimulated LTR. These results indicate that FHV-1 ICP4 possesses both abilities to transac‐
tivate or down-regulate FIV-directed gene expression. C/EBP and AP-1 regulatory
sequences are known to act as both positive and negative regulators [44]. Interestingly
enough, plasmids expressing ICP4 homologues of Alphaherpesviruses, namely pseudora‐
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bies virus (PRV) and equine herpesvirus type 1 (EHV-1) could significantly inhibit FIV LTR-
directed gene expression in CrFK and fcwf-4 cells. Moreover, the ICP4 homologues also
exhibited a marked suppressive effect on FIV replication in CrFK cells cotransfected with an
infectious clone of FIV [45]. These experiments drow attention to the role of other herpesvi‐
ruses, among them Roseoloviruses [46], which might exist in cats. Similarities and differen‐
ces between the human or feline AIDS could help elucidating their devastating role in
human and feline patients.
3.2. Feline adenovirus
Among other DNA viruses, adenovirus (AdV) also might enhance AIDS progression in cats.
So far, the only feline adenovirus (FeAdV) isolate (also the first one from the family Felidae)
was obtained from a fecal sample of a cat with AdV PCR positivity [47] and unknown FIV
serostatus [48]. Its hexon [49], fiber [50], and nucleotide sequences published so far suggest
that it might be related to human AdV type 1 (HAdV-1). Similar nucleotide sequences have
been shown in the feces of a small child suffering with gastroenteritis and her cat in Japan
[51], and in one nasopharyngeal aspirate sample of a 468 member cohort of children present‐
ing acute respiratory disease in Brazil [52]. This virus might be widespread all over the
world and one can speculate that it could transactivate both HIV and FIV, e.g. in pet owners.
Seroepidemiological studies show that approx. 10-20% of free roaming cats are seropositive
in Hungary and Europe [53,54]. In a series of consecutive transfer of FIV by intravenous in‐
oculation of experimental SPF casts, four were AdV seropositive, but their serostatus before
FIV inoculation remained unknown. One can speculate that accidental transfer of AdV
along with FIV occurred [55]. FeAdV would be ideal to compare its unique clinical and mo‐
lecular effects in the human and the cat both in vivo and in vitro similarly to studies on the
interaction of HHV-6 and SIV in humans and pig-tailed macaques [56,57]. As it was isolated
from cat feces, one could use FeAdV and FIV to model intestinal molecular interaction of
HAdVs and HIV.
3.3. Feline leukaemia virus
Another common interaction in nature is between FIV infection and FeLV. FeLV is of partic‐
ular significance because it can also induce immunodeficiency [58]. FeLV is a homologue of
human T lymphotropic virus (HTLV). It displays a prevalence of 1-8% worldwide
[16,24,33,38], but in some geographical areas much higher prevalence of FeLV antigen has
been detected (14.2% in Iran, [21], 24.5% in Thailand, [18], 26% in Portugal, [28]). In catteries
its prevalence could be much lower or up to zero [17,26,30,32]. Its prevalence has been de‐
creasing in most countries and is regarded as a less important deadly infectious agent in the
last 20 years compared to FIV [19]. In confined geographical regions or among captive ani‐
mals in different facilities, simultaneous decline in the seroprevalence of both FeLV and FIV
has also been observed [29,33]. Seroprevalence is higher in intact males than females, and
increases with age [17,18]. Transmission is usually by direct contact or saliva wounds. FeLV
infection among non-domestic cats of the Felidae family is rare, but FeLV has been shown to
cross species barriers, especially in case of prior or simultaneous microbial immunosuppres‐
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sion [12,28]. There are four naturally occurring exogenous FeLV strains: FeLV-A, -B, -C, and
–T. FeLV-A is the predominant subgroup circulating in feral cats. Its integrated proviral se‐
quences are transmitted vertically through the germ line. Recombination might occur be‐
tween FeLV-A and other subgroups. The outcome after exposure depends on several host
and environmental factors, but the clinical course is more aggressive than seen with FIV. In
approximately one third of exposed cats, viraemia is persistent and eventually results in
clinical disorders such as immunosuppression, bone marrow suppression (mainly anaemia),
and neoplasm (mainly lymphoma) [12,19]. Like FIV, FeLV infection alone also renders the
animals more susceptible to infection, persistence and disease elicited by heterologous mi‐
crobes [19,28,33] such as TG [21] or BH [36]. Mortality among persistently FeLV infected cats
is high as 83% die within 3.5 years [references in 12]. About 10 to 15% of the cats that are
clinically ill with FIV infection are coinfected with FeLV worldwide [59,60]. Upon superin‐
fection with FIV, asymptomatic cats with persistent FeLV infection manifest a more acceler‐
ate and exacerbated FIV disease, anticipated death and show a higher FIV load in lymphoid
tissues than did naive cats under both natural and experimental conditions, while the blood
level of FeLV p27 antigen was not elevated. Interestingly, the synergy between FIV and
FeLV is bidirectional: doubly infected cats develop FeLV induced tumours more frequently
than did cats infected with either virus alone [61]. Dually infected cats remain more leuko‐
penic than cats infected with FIV or FeLV alone, and their CD4+/CD8+ T lymphocyte ratios
become rapidly inverted [62]. This interrelationship is similar to what has been described for
HIV and HTLV-I [63].
3.4. Simultaneous Listeria and FIV infection
Scarce data are available on the possible effect on FIV and FAIDS exerted by feline bacterial
infections. Listeria monocytogenes (LM) can infect both humans and cats, and its profound im‐
munomodulatory capabilities are well known. Beside HIV, both FIV and LM impair the in‐
nate immune response that fails to gain control of their replication prior to the adaptive
immune response. These effects might be additive or synergistic in simultaneously infected
individuals. In a series of recent experiments, chronically FIV infected and SPF control cats
were challenged with LM, then their whole blood and lymph nodes were collected 3 days
after challenge. The number and functions of natural killer (NK) cells (CD3-CD56+), NKT
cells (CD3+CD56+), CD4 (CD3+CD4+), CD8 (CD3+CD8+), regulatory T cells
(CD4+CD25+Fox3+) and Langerhans cells (CD1a) were evaluated. NK, NKT, CD4+ and
CD8+ T cells in the LM challenged lymph node of FIV-infected cats did not increase in num‐
ber, NK cells did not increase their proliferation, apoptosis was elevated, and perforin ex‐
pression was not upregulated when compared to SPF control animals. No difference in Treg
cell number was found. Delayed control and clearance of opportunistic LM was also ob‐
served. In the blood compartment of LM challenged cats, CD4+ T cell proliferation did not
differ in SPF-control and FIV positive cats, while CD8+ T cell proliferation increased in FIV-
positive animals. The number of Langerhans cells did not decrease in FIV and LM infected
animals, but their ability to produce NK-activating IL-15 and other mediators became im‐
paired. Although it is concluded that FIV-infected cats are more vulnerable to LM superin‐
fection [2], it is conceivable that precedent or ongoing Listeria infection diminishes the
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activity of NK cells, helps promote FIV replication and dissemination in the body of ani‐
mals. In HIV-infected patients, dysfunction of NK cells with low perforin expression, aner‐
gy, furthermore, abnormal antigen presentation and low level of IL-15, IL-12 levels are also
known [2]. In humans, infection by LM or other bacteria with immunosuppressive potential
might augment impaired immunosurveillance, consequently increase HIV load, and ulti‐
mately facilitate AIDS progression.
3.5. Feline haemotropic mycoplasmas (haemoplasmas)
Epidemiological surveys on simultaneous infections by FIV and feline haemophilic myco‐
plasmas suggest that opportunistic infections also promote FIV progression. Feline haemo‐
philic mycoplasmas (Mycoplasma haemofelis, Candidatus Mycoplasma haemominutus)
collectively called haemoplasmas can cause anaemia and severe clinical disease of affected
cats. Candidatus Mycoplasma haemominutus (CMH) is usually not associated with clinical dis‐
ease, but typically causes anaemia in cats carrying pre-existing FIV or FeLV infection
[29,64,65]. Chronic FIV infection appears to modify the acute phase response to feline hae‐
motropic mycoplasmas, which varies with the infecting haemoplasma species, namely CMH
and M. haemofelis (MH), respectively [64]. A recent study in a Canadian feral cat population
found that CMH positive cats were significantly more likely to be concurrently retrovirus
positive than were CMH negative animals [33]. Another recent study in Spain found that,
FIV seropositivity and male sex were significantly associated with MH, CMH and Ca. M. tu‐
ricensis infection [27]. It is of note, that mycoplasmas in HIV infected patients have been re‐
garded as AIDS promoting factors for a long time, and this phenomenon was proved in
vitro, either [66]. A meta-analysis of former studies unambiguously demonstrated that geni‐
tal infection by M. genitalium poses high risk for acquisition of HIV. Testing and treatment of
M. genitalium-positive individuals in high risk groups is recommended as a potential HIV
prevention strategy [67]. Bacterial vaginosis-associated microflora in the female genital tract
also predisposes for HIV infection. Among flora members, M. hominis was shown to activate
NF-κB and AP-1. Through mediation of a soluble HIV inducing factor (HIF), these transcrip‐
tional factors may subsequently increase genital tract viral load and potentially contribute to
HIV transmission [68]. MH infection along with BH infection has been verified by PCR in an
HIV infected person [69]. The 34 year old man owned several cats. Haemoplasma DNA is
present in saliva and feces of cats, which suggests that aggressive interactions among cats
and humans involving biting may lead to transmission of the organism. So far, haemotropic
mycoplasma infections have been reported in a patient with systemic lupus erythematosus
(SLE) and in an anaemic patient showing that some forms of immunosuppression are re‐
quired for acquisition of an unusual pathogen [70]. Increasing number of human patients
with compromised immune systems living near cats increases the possibility that haemo‐
plasma infections may emerge in this population [69]. Haemoplasma positive cats like my‐
coplasma positive humans ought to be regarded at increased risk for retrovirus infection.
Testing would also be appropriate prior to relocation of felids [29]. Feline mycoplasmas
could provide a unique model to clarify the exact role of mycoplasmas in AIDS progression.
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3.6. Feline mycobacteria
Mycobacteria are important opportunistic infections in HIV infected patients worldwide. Es‐
pecially in Sub-Saharan Africa very aggressive forms of tuberculosis occur in the immuno‐
compromised population induced by several mycobacterium species. Mycobacteria severely
suppress activities of the cellular immune reactions but due to the difficulties in their culti‐
vation and the chronic nature of the disease, it is extremely difficult to study their mutual
effects on the immune system. Several mycobacterium species that infect the human and are
prevalent in HIV infected patients (e.g. M. bovis, M. avium, M. microti), induce disease in cats
[23]. This finding raises the idea that FAIDS would be an appropriate model to study inti‐
mate relationship between mycobacteria and feline retroviruses in vivo.
Repeated exposure of FIV positive cats to bacterial lipopolysaccharide endotoxin (LPS) re‐
sulted in lower plasma and brain viremia. In HIV infected humans and FIV infected cats,
macrophages produce elevated amount of specific chemokine CXCL10, which in turn dam‐
ages brain cells. LPS treatment of infected macrophages release IL-10 counteracting CXCL10
expression of brain cells. Suppressed CXCL10 level in the brain of FIV-positive cats and en‐
suing T cell infiltration is concomitant with reduction in neurovirulence [71]. This observa‐
tion is in correlation with earlier results, namely that LPS treatment of HHV-6A infected
lymphoid cells decrease expression of such soluble mediators that transactivate HIV-1 in
other lymphoid cultures [3].
3.7. Fungal and parasitic infections in FIV infected cats
Humans and cats can be infected by several common fungal pathogens, such as Cryptococ‐
cus [22], Malassezia, Microsporum [26] and others [28]. Dermatophyte fungi were isolated in
29.4% from stray cats in Portugal [28]. Microsporum gypseum and, occasionally, M. canis were
found in an equal ratio of FIV negative and positive cats (8 and 8.5%, respectively). In con‐
trast, Malassezia species were more frequently isolated from FIV infected cats than FIV-un‐
infected cats (84% vs. 28.6%) thus showing a closer biological relationship in the effect of FIV
and certain fungal species. The CD4:CD8 ratio for FIV infected cats with cutaneous overall
fungal infection was significantly lower than the CD4:CD8 ratio in the FIV infected cats but
without cutaneous fungal infection. It is obvious that worsening cellular immunity repre‐
sents a risk factor to cutaneous fungal colonisation in cats [26], but existence of a cutaneous
or systematic fungal infection due to insufficient activity of the cellular immunity acquired
by inherent or environmental effects might also make easier to acquire FIV infection. Dam‐
aged local immunity in the skin in case of wound FIV infection could be one of the most
frequent examples. Cats having human or human homologues of fungal species would be
ideal models to study such aspects.
Cats having access to the outdoor world, very easily acquire parasitic infections. Feral cats
can serve as a direct or indirect source of infectious diseases for pet cats. Contact with ani‐
mals of other species, conditions of breeding, food supply and age are considered significant
for infections. A recent study conducted in a Brazilian cat colony free from FIV, FeLV and
Neospora caninum infection, clearly showed these differences. Of cats from urban and rural
areas, 10.4% and 27.2% were seropositive for TG, respectively. Cats having access to streets
Interaction of FIV with Heterologous Microbes in the Feline AIDS Model
http://dx.doi.org/10.5772/52767
455
(17.1%), cats cohabiting with rats (19.6%), and cats feeding on homemade food and raw milk
(27.2%) were positive for this protozoon. In addition, 4.2% of cats were positive for Leishma‐
nia spp. [30]. In several countries, parasitic infections, especially intestinal parasites, of cats
are more frequent than infections with FIV or FeLV. In Italy, comparison of FIV, FeLV and
TG IgG seropositivity resulted in the same ratio: 6.6%, 3.8% and 30.5%, respectively [11]. Ep‐
idemiological studies in Portugal found 24.2% TG seropositivity, 31% carrier state of intesti‐
nal parasites (Toxocara cati, Isospora felis, Ankylostoma stenocephala, Toxascaris leonina) as
compared to FIV and FeLV infection (10.2% and 7.1%, respectively) in the same stray cat
population [28]. In a confined region of Canada, 29.8% of cats had TG antibodies, 1.3% ex‐
creted oocysts in their feces, while FIV and FeLV seropositivity was significantly lower
(5.2% and 3.1%, respectively [33]. In Thailand, although the ratio between retroviral and
parasitic infections were different (FIV, FeLV, heartworm (Dirofilaria immitis) and TG IgG
(20.1%, 24.5%, 4.6% and 10.1%, respectively) from the other data mentioned above, of the
348 cats sampled for all four pathogens, 3.1%, 2.8% and 0.28% were positive for TG antibod‐
ies and FIV antibodies, FeLV antigen or D. immitis antigen, respectively. Of the 35 TG sero‐
positive cats, 42.9% were coinfected with at least one of the other three pathogens [18]. Feral
cats from Cairo, Egypt exhibited an extremely high ratio of TG infestation as compared to
FIV, FeLV of heartworm seroprevalence: 95.5%, 33.9%, 4.6% and 3.4%, respectively. It is of
interest that 57.4% of TG positive cats had very high antibody titre (>1:640) [31]. Oocyst
shedding was found to be accompanied by high level antibodies: cats shedding TG had high
antibody level (>1:256). In the same cat cohort, Toxocara cati eggs were identified in 37%, Cys‐
toisospora felis oocysts in 14%, Taenia sp. segments in 15% of animals. Most of the fecal sam‐
ples showed evidence of at least one intestinal parasite, while many samples contained
evidence of multiple intestinal parasites. High prevalence of antibodies reflects latent infec‐
tions. However, it must be emphasized that cats with latent infection can pose a considera‐
ble zoonotic risk with respect to the shedding of intestinal parasites in their feces. Stress
conditions induce shedding. Intercurrent retroviral infections (FIV or FeLV or both) with
consequent declination in systemic and mucosal immunity are regarded as important stress
factors [33]. Result of the multivariate logistic regression analysis of another recent survey
on simultaneous virus and parasite seropositivity (FIV, FeLV and TG was 19.2%, 14.2% and
32.1%, respectively) in Iran showed that retroviral-associated immunosuppression is a risk
factor for activation of toxoplasmosis in cats [21]. Beside toxoplasmosis, Leishmania infec‐
tion is frequent in many countries. Cellular immunity of normal cats effectively controls
Leishmania infantum (syn. L. chagasi). However, feline immunosuppressive diseases such as
FIV and FeLV infection impair the normal response to infection and expose cats to reactiva‐
tion or new infections by other pathogens, among them Leishmania. Although no statistical
evidence of association between TG and Leishmania was found, but in cats coinfected with
FIV, a strong statistical association for the triple coinfection was found [16]. One can con‐
clude from these epidemiological surveys, that parasites cause not only opportunistic infec‐
tions in retrovirus infected cats, but activation of their latent infection by retroviruses
suggests existence of a closer relationship between phylogenetically distant two groups of
foreign agents at molecular or immunological level.
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Following infection of FIV carrier cats with a secondary pathogen, cytokine dysregulation is
more pronounced. TG increases both IFN-γ and IL-10, but fails to increase IL-2, IL-12, while
TG infected FIV negative cats show an increase in IFN-γ, IL-2 and IL-12 [72]. A similar dys‐
regulation has been reported in cats challenged with LM [73]. The increase in IL-10 to IL-12
ratio predicts the loss of cellular immunity in FIV infected cats [72,74]. These in vivo studies
are in good correlation with in vitro experiments. Latent infection in HIV or FIV infected
lymphocytes and macrophages can be reactivated and virus production can be increased by
chemical immune activators such as phorbol myristate acetate [75], concanavalin A [5],
granulocyte macrophage-colony stimulating factor [76]. Both HIV and FIV induce apoptosis
not only in the infected cells, but in the vicinity of infected cells as well. Programmed cell
death of infected cells is mediated mainly by TNF-α released from infected cells [77]. Cyto‐
kine dysregulation affects not only the FIV carrier animal, but damages the fetus by causing
a pro-inflammatory placental microenvironment at early pregnancy: increased expression of
IL-6, IL-12, decreased expression of IL-1β, SDF-1α. Similarly to AIDS patients, IL-6 expres‐
sion correlated with FIV load [78]. The exact role of cytokines and chemokines in the process
of simultaneous infections waits for clarification.
4. Diagnosis, treatment and prevention of simultaneous infections
Preventing exposure of healthy cats to FIV or FeLV infected cats by tests and removal or iso‐
lation is an important measure, and is not alternative to vaccination. The most common
method for diagnosis of FIV infection is screening for antibodies (typically against p24 and
p15) using an ELISA. Several commercial kits are available worldwide. Confirmatory testing
for cats with positive results is strongly recommended, Western-blot and immunofluores‐
cent antibody assays (IFA) are used. Infection from queens can be transmitted to kittens,
testing for newly acquired cats and kittens is strongly recommended. Vaccinated cats also
produce antibodies that cannot be distinguished, by any commercially available antibody
test [79], from antibodies due to natural infection, and queens might transmit these antibod‐
ies to the litter via colostrum. FIV vaccine induces fewer antibodies for non-structural pro‐
teins compared to natural infection. There are tests to discriminate this pattern, but these are
unsuitable for routine use. Polymerase chain reaction (PCR) has promoted by some com‐
mercial laboratories as a method to determine a cat’s true infection status. The test detects
FIV RNA or proviral DNA. A real-time PCR assay for FIV quantification of proviral DNA in
PBMC has high sensitivity and specificity. This and reverse transcriptase (RT)-PCR are
methods to quantitate viral load and dissemination in the body after activation of latent FIV
infection. Due to genetically heterologous nature of FIV, tests with concurrent determination
of subtype differentiation are recommended. Serological diagnosis of FeLV relies on detec‐
tion of the core antigen p27 in PBMC using an ELISA. IFA test is also used but discordant
results might occur. PCR is offered by a number of commercial laboratories, it can be per‐
formed on blood, saliva, bone marrow and tissues. Kittens can be tested for FeLV at any age,
as passively acquired maternal antibody does not interfere with testing for viral antigen.
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Compliance of cat owners with FIV and FeLV testing is low, in spite of using combined test
kits, and professional recommendations by veterinarians (Table 1).
At risk of infection
cats access to outdoors





Cats entering new homes, shelters
Newly acquired cats and kittens about to be
vaccinated for FIV or FeLV
Cats used for blood or tissue donation
Table 1. Major recommendations for FIV and FeLV testing of cats
The owner must also consider the cost of immunisation, fecal parasite testing, de-worming,
or blood screening to reveal and eliminate concomitant infections [17]. Further commercially
available kits for serological screening, and/or antigen detection including FHV-1 and the
most pathogens are widely available for domestic and large cats. These kits used separately
depending on the clinical course of the animal can be combined in definitively. Well estab‐
lished, cheap but somewhat laborious and time consuming classical methods have been
used for direct detection of common bacteria, fungi and parasites (cultivation, biochemistry,
microscopy, etc.). For feline pathogens causing infection in humans, the same methods and
kits can be used as in human medicine. With technological advances quantitative real-time
or RT-PCR assays have been used subsequently their products are sequenced to determine
species or variants. Load of viruses in body fluids can be determined by quantitative molec‐
ular methods [5,7,24,36]. Simultaneous detection of nucleic acids of coinfecting microbes
would be ideal by using multiple PCR [20, 29]. Development of easily available panels is a
financial interest of biotechnology companies. Gene arrays capable of detecting even hun‐
dreds of microbes at nucleic acid level could also be marketed in near future.
Aims of detecting simultaneous infection in cats and large felids are very variable. As retro‐
viral infection might represent a considerable risk factor to several bacterial, fungal and par‐
asitic opportunistic infections and activating potential of their latency, demonstration of
retroviruses ought to be followed by screening for other pathogens [21]. Vice versa, cats liv‐
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ing in endemic areas of certain parasites are significantly more likely to be co-infected with
FIV and/or FeLV, which may present confounding clinical signs and therefore cats in such
areas should be always carefully screened for coinfections [16]. Occasionally, knowing the
cat’s geographical location can be helpful, while the nature of the clinical presentation might
be less informative [23]. Informations concerning risk assessment of viral pathogens to other
animal populations are currently an important issue [28]. Screening for multiple infections is
appropriate prior to relocation of cats and other felids to prevent introduction of pathogens
in host colonies (households, catteries, zoos, national parks, etc.) [29]. As with HIV, careful
consideration should also be given to systematic testing and treatment of individuals in
high-risk populations, and this may prove to be a potential strategy to prevent FIV transmis‐
sion [67]. Preventive measures are important, because transmission of pathogens in cluster
conditions may occur between asymptomatic cats and immunocompromised animals
[25,32]. Furthermore, certain FIV or FeLV strains are able to emerge in new host species. Do‐
mestic cat strains of viruses can cross species barriers with potentially devastating conse‐
quences to fragile populations of large felids [12]. As seen with feline haemoplasma, it could
infect even the immunocompromised human cat owner [69] so; cat owners ought to be pro‐
tected from common zoonotic infections.
While testing and identification of infected cats is necessary for prevention and transmis‐
sion, vaccination is also an important tool. Various independent bodies, including the Inter‐
national Vaccination Guidelines Group (IVGG), the European Advisory Board on Cat
Diseases (ABCD), the World Small Animal Veterinary Association (WSAVA), or the Ameri‐
can Association of Feline Practitioners (AAFP) have developed and regularly issues recom‐
mendations for vaccination protocols for cats and kittens. The guidelines encompass the
types of antigens used, the types of vaccines available, the frequency of vaccination and the
anatomical site used for administration. These guidelines differ from each other and also
from the manufacturer’s datasheets or recommendations of national authorities. General as‐
pects and details of vaccination of cats are far beyond the scope of recent review; in this re‐
gard see a recent publication by Dean et al. 2012. Core vaccines are defined as those vaccines
which all cats, regardless of circumstances, should receive to protect animals from severe,
life threatening diseases which have global distribution. Only to emphasize those in context
with microbes with transactivating and opportunistic potential, FHV-1 vaccination of kittens
seems to be important. Vaccination against FCV, FPV also belongs to core vaccines. These
vaccinations are recommended to start as early as vaccination with FeLV, applying revacci‐
nations up to 16-20 weeks of age. Most practices routinely give the commonly used antigens
annually, although with the exception of the FHV, the FCV and FIV vaccination is recom‐
mended every 3 years [80]. Non-core vaccines are those that are required by only those ani‐
mals whose geographic location, local environment or lifestyle place them at risk of
contracting specific infections. This moment, both FIV and FeLV vaccines are regarded as
non-core. FIV vaccine development was initiated as a model for HIV vaccination. Vaccina‐
tion against HIV started with experiments to trigger a specific, potent and long-lasting im‐
munity in a surrogate animal model. Later, several novel approaches were tested in the
feline model. Although the quest for a truly effective AIDS vaccine is years away [81], vacci‐
nation against FIV became available [82]. This vaccine (Fel-O-Vax FIV®) is marketed in many
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countries, but it might not protect cats against all field strains of subtypes A or B. Lifespan of
infected cats appears similar to that of uninfected cats, but exposure to other infectious dis‐
eases drastically reduces survival of FIV positive animals [17]. Historically, FeLV vaccina‐
tion has been used for decades, well before FIV vaccination. The combined use of testing
and vaccination programs is assumed to have decreased the prevalence of FeLV over the
last 20 years [17,19]. Administering the first vaccine to kittens is at 8-10 weeks of age, with
regular revaccinations usually every year. Several practitioners stopped revaccinating in‐
door and older cats, once they reached a certain age (≥ 6 years) assuming that they would
not have close contact with a persistently infected cat, or elder cats are less easily infected
with FeLV than younger animals. As persistently infected cats have been diagnosed at all
ages, due to the decreased susceptibility to FeLV infection, vaccinating at 2-3 years intervals
rather than annually seems to be acceptable. For free-roaming cats, annual FeLV vaccination
is recommended. To increase revaccination interval assuming the presence of high level an‐
tibodies is not feasible because quantitative assays to measure serum FeLV antibodies are
commercially available in few countries [80]. A marked difference in vaccination efficacy ex‐
ists, and suggests that only inactivated whole virus or canarypox-vectored recombinant vac‐
cines should be used. Cats with access to outdoors should be vaccinated, but should have at
least one negative FeLV ELISA test before vaccination. Several studies showed that the
mean survival time of FeLV positive cats are significantly shorter than that of FeLV-negative
cats including vaccinated ones (references in 17). Aspecific measures to prevent FIV and
FeLV transmission were set according to the biological characteristics of these viruses. Al‐
though retroviruses become inactivated within a few hours on dry surfaces, they may re‐
main viable in dried biological deposits for more than a week. Both viruses are inactivated
by common detergents and hospital disinfectants. Spreading via body fluids is best prevent‐
ed by single set of instruments in clinical practice. To prevent infections by other microbes,
including those with transactivation or opportunistic potential, hospitalised cats should not
be allowed to have direct contact with one another. It is important not to keep retrovirus-
infected cats in contagious disease ward as they are potentially immunosuppressed and car‐
ry or acquire other pathogens [17]. A recent survey in the UK showed that several
veterinarians are not aware of the guidelines, or they do not adhere to them. Similarly to
guidelines in human healthcare, other barriers included lack of agreement or lack of ability
to follow guidelines, lack of motivation to follow them, and lack to perceive benefits to pa‐
tients. The frequency, combination and selection of antigens routinely given to cats by veter‐
inarians remain unknown, as are the anatomical sites to inject cats. Therefore, the impact of
the published guidelines on practitioners working also remains unknown [80]. Further work
is required to elicit why following guidelines may reduce occurrence and severity of both
opportunistic infections and halt onset and slow progression of FAIDS by eliminating infec‐
tion by other microbes.
The FIV/cat model has provided a unique opportunity to test novel therapeutic interven‐
tions aimed at eradicating latent virus, but the use of antiretroviral drugs in FIV infected
cats and other felids has not gained grounds in the routine veterinary practice [7,8]. Several
conventional microbial coinfections are treated with routine medication.
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5. Conclusions
Descriptive epidemiological surveys on the simultaneous infection by feline retroviruses,
namely FIV and/or FeLV, and heterologous microbes clearly show that progression of
FAIDS is facilitated by certain viruses, bacteria and other parasites that also induce oppor‐
tunistic infections in a vicious circle. Scarce experimental data suggest that FIV transactivat‐
ing potential of heterologous microbes might increase FIV load, facilitate FAIDS course, and
help induce malignancies resulting in considerably impaired quality of life and shorter life
span of afflicted domestic cats. Simultaneous cross-species transmission of infection by par‐
ticular FIV and FeLV strains in endangered big cats may also occur. Emerging infections by
FIV transactivating and opportunistic feline microbes in immunocompromised humans
have already been described. Additive or synergistic impairing effects on the native immune
reactions, activation of negatively affecting Treg cells, depression of cytotoxic T cell activi‐
ties, and abnormal cytokine pattern exerted by heterologous microbes demonstrate striking
similarities between AIDS and FAIDS. Regular vaccination against transactivating microbes
(e.g. FeLV, FHV-1) and transactivated microbe (FIV) starting at early age prevents and dis‐
rupts deleterious microbial interactions. These result in a complete halt or a significant slow‐
down of acquired immunodeficiency states. Experience verified in the feline model enables
us to continue studying microbial interactions at molecular, cellular, immunological or clini‐
cal levels. Further experiments are warranted to better delineate the role of putative cofac‐
tors in FIV infection. Further studies should examine concurrent infections as contributing
factors in the development and progression of neoplasia in FIV-positive cats. Determination
of viral cooperative mechanisms that promote cancer during co-infection would be highly
relevant to both FIV- and HIV-related diseases.
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